POM-V Prescription Required

Cyclofin 300 mg/ml + 20 mg/ml Solution for Injection for Cattle

Active ingredients: Flunixin, Oxytetracycline

Form

Injection

Species

Cattle

Manufacturer

Dechra Regulatory B.V.

VMD MA No.

50406/5046

What it's used for

For the treatment of bovine respiratory disease caused by Mannheimia (Pasteurella) haemolytica where an anti-inflammatory and anti-pyretic effect is requir...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin + Oxytetracycline

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cyclofin 300 mg/ml + 20 mg/ml Solution for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the treatment of bovine respiratory disease caused by Mannheimia
(Pasteurella) haemolytica where an anti-inflammatory and anti-pyretic effect is
required.

Indicated for deep intramuscular administration to cattle.
The recommended dosage is 1 ml per 10 kg bodyweight (equivalent to 2 mg/kg
flunixin and 30 mg/kg oxytetracycline).
To ensure a correct dosage, bodyweight should be determined as accurately as
possible. The veterinary medicinal product is recommended for administration
on a single occasion only. Maximum volume per injection site: 15ml.
If concurrent treatment is administered use a separate injection site.

Do not use in in animals suffering from cardiac, hepatic, or renal disease,
where there is a possibility of gastrointestinal ulceration or bleeding.
Do no use in dehydrated, hypovolaemic or hypotensive animals as there is a
potential risk of increased renal toxicity.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.

Revised: July 2025
AN:00630/2025
Do not use the veterinary medicinal product where there are signs of blood
dyscrasias or haemostasis alteration.

Cattle:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reactions
a
Undetermined frequency
(cannot be estimated from the
available data)
Injection site reaction
b
, Mild increase in body
temperature
c
, Dental discoloration
d
, Bone
discoloration
d

a
May occur, which can be fatal.
b
A usually mild reaction at the injection site may be observed following
intramuscular administration and may persist for up to 30 days. Studies in cattle
at the normal dose rate have shown transient and dose dependent reactions at
the injection site.
c
Any increase is transient and will be unlikely to occur in animals already
suffering from pyrexia.
d
The use of tetracyclines during the period of tooth and bone development may
lead to discoloration.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the national competent authority via the national reporting
system or the marketing authorisation holder (or their local representative). See
the package leaflet for contact details.

Cross-resistance has been shown between oxytetracycline and other
antimicrobials belonging to the tetracyclines class in Mannheimia (Pasteurella)
haemolytica. When susceptibility testing has shown resistance to other
tetracycline antimicrobials the use of oxytetracycline should be carefully
considered because its effectiveness may be reduced.

i) Special precautions for use in animals
Use in any animals less than 6 weeks of age or in aged animals may involve
additional risk. If such use cannot be avoided, animals may require a reduced
dosage and careful clinical management.
It is preferable that prostaglandin inhibiting drugs are not administered to
animals undergoing general anaesthesia until fully recovered.
Use of the veterinary medicinal product should be based on identification and
susceptibility testing of the target pathogens. If this is not possible, therapy
should be based on epidemiological information and knowledge of susceptibility
of the target pathogens at farm level, or at local/regional level.
Use of the veterinary medicinal product should be in accordance with official,
national, and regional antimicrobial policies.
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible
to enter wild fauna food chain. In case of death or sacrifice of treated animals,
ensure that they are not made available to wild fauna.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This veterinary medicinal product may be harmful after accidental self-injection.
In case of accidental self-injection seek medical advice immediately and show
the package leaflet or the label to the physician.
This veterinary medicinal product may be irritating to the skin and/or eye. Avoid
skin and/or eye contact. Latex or nitrile gloves should be worn during application.
In case of accidental contact with skin or eyes, rinse with copious amounts of
water. If irritation persists, seek medical advice.
This veterinary medicinal product may cause hypersensitivity reactions due to
the presence of oxytetracycline, flunixin, polyethylene glycol or ethanolamine.
People with known hypersensitivity to tetracyclines, NSAIDs or one of the
excipients should avoid contact with the veterinary medicinal product. If allergic
symptoms develop, such as a skin rash, swelling of the face, lips or eyes or
difficulty in breathing, you should seek medical attention immediately and show
the package leaflet or label to the doctor.

Revised: July 2025
AN:00630/2025
Daily exposure of laboratory animals (rats) to glycerol formal results in
teratogenic and foetotoxic effects. Pregnant women and women of child-bearing
age should take particular caution to avoid exposure when administering the
veterinary medicinal product.
iii) Other precautions

Concurrent use of potentially nephrotoxic drugs should be avoided (e.g.
aminoglycosides). Flunixin may reduce the renal excretion of certain veterinary
medicinal products and increase their toxicity, such as for aminoglycosides.
Some NSAIDs may be highly bound to plasma proteins and compete with other
highly bound drugs which can lead to toxic effects.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Additional therapy with a NSAID may be administered after 24 hours if required.
Concurrent use of corticosteroids should be avoided.
Flunixin may reduce the effect of some anti-hypertensive medicinal products,
such as diuretics and beta blockers, by inhibition of prostaglandin synthesis.

This medicinal product does not require any special storage conditions.
Following withdrawal of the first dose, the product should be used within 28
days. Discard unused material.

Meat and offal: 35 days
Not authorised for use in cattle producing milk for human consumption

Revised: July 2025
AN:00630/2025
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.